Clinical Trials Logo

Filter by:
NCT ID: NCT04852718 Recruiting - Covid19 Clinical Trials

Rehabilitation Program for the Sequelae of COVID 19 Infection

ISIS
Start date: April 13, 2021
Phase:
Study type: Observational

SUBPROJECT 1: Describe the situation of post-Covid patients in terms of muscle (skeletal and respiratory), cognitive, emotional and health-related quality of life in the 1st visit of the multidisciplinary post-covid rehabilitation consultation at the Hospital. Retrospective observational study. The data collected in clinical records during the first visit in the post-covid Rehabilitation consultation will be analysed. SUBPROJECT 2: Evaluate the response to a personalized rehabilitation program in patients with post-covid sequelae in terms of muscle (skeletal and respiratory), and health-related quality of life. Prospective observational study of a single cohort of patients. The data will be collected from successive clinical visits.

NCT ID: NCT04851795 Recruiting - Anxiety Clinical Trials

Effectiveness of a Supervised Hospital-based Physical Exercise

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

To assess if physical activity is effective in reducing stress and anxiety in healthcare professionals.

NCT ID: NCT04850105 Recruiting - Clinical trials for Hereditary Transthyretin Amyloidosis With Polyneuropthy

A Non-interventional Cohort Safety Study of Patients With hATTR-PN

Start date: September 21, 2021
Phase:
Study type: Observational

This is a prospective, non-interventional, Long-term, multinational cohort safety study of patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (hATTR-PN). The overarching goal of this study is to further characterize the long-term safety of TEGSEDI (inotersen) in patients with hATTR-PN under real-world conditions.

NCT ID: NCT04849728 Recruiting - Clinical trials for NASH - Nonalcoholic Steatohepatitis

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NATiV3
Start date: August 19, 2021
Phase: Phase 3
Study type: Interventional

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

NCT ID: NCT04848883 Recruiting - Infectious Disease Clinical Trials

Infectious Diseases Experts as Part of the Antibiotic Stewardship Team in Primary Care

IDASP
Start date: June 1, 2021
Phase: N/A
Study type: Interventional

A cluster-randomised multicentre blinded clinical trial will be performed in six primary care centres located in the southern metropolitan area of Barcelona (Spain). The objective is to assess whether including experts on infectious diseases (ID) within the antimicrobial stewardship (AMS) team of primary care achieves higher reductions on overall antibiotic consumption and increases the quality of prescription in diagnosed upper respiratory and urinary tract infections. Centres will be randomly assigned to receive a standard-AMS or an advanced-AMS (intervention). Advanced-AMS includes all standard-AMS strategies plus general practitioner chance to discuss clinical cases by telephone to ID expert on working days (8:00 am to 8:00 pm), and by biweekly meetings.

NCT ID: NCT04848779 Recruiting - Clinical trials for Glycogen Storage Disease Type II

A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)

Start date: June 10, 2021
Phase:
Study type: Observational [Patient Registry]

Primary Objective: To describe the effect of routine practice with alglucosidase alfa in patients with IOPD ≤6 months of age, on invasive ventilation-free survival after 52 weeks of treatment. Secondary Objectives: - To describe the effect of routine practice with alglucosidase alfa on invasive ventilation-free survival and survival at 12 and 18 months of age, as well as on change in left ventricular mass (LVM) Z score, Alberta Infant Motor Scale (AIMS) score, body weight, body length, and head circumference Z scores, and urinary glucose tetrasaccharide (Hex4), at Week 52 of treatment. - To describe the safety, tolerability, and immunogenicity of alglucosidase alfa in the routine practice of IOPD treatment.

NCT ID: NCT04848298 Recruiting - Heart Failure Clinical Trials

Use of mHealth to Increase Physical Activity for Patients Recently Hospitalized With Acute Heart Failure

mRehab
Start date: April 22, 2021
Phase: N/A
Study type: Interventional

The aim of this trial is to determine if a mobile application that promotes physical exercise in the follow-up of patients recently hospitalized with acute heart failure can improve exercise capacity after 6 months and physical activity levels compared to the standard follow-up. A randomized clinical trial will be conducted with 100 consecutive patients aged +18 years, hospitalized for acute decompensated heart failure in a tertiary referral hospital who own a mobile phone compatible with MyPlan and access to Wi-Fi or mobile data. At discharge, patients will be randomly assigned in two groups; the intervention group will be followed with a smartphone application to promote physical activity, whereas the control group will take responsibility in their adherence to exercise recommendations. Main study variables will be functional capacity after 6 months, which will be evaluated using the six minute walking test, and physical activity levels, using the International Physical Activity Questionnaire (IPAQ). The study will be analyzed using the intention-to-treat principle. The project has been authorized by the local committee for ethics in clinical research.

NCT ID: NCT04847713 Recruiting - Fabry's Disease Clinical Trials

Early Detection and Follow-Up of Patients With Fabry's Disease

Start date: January 1, 2021
Phase:
Study type: Observational

This research project will serve on the enhancement of early detection, diagnosis and follow-up of patients with Fabry Disease, through new biomarkers identification. This could have straight clinical impact on: 1. Early diagnosis, follow-up, and prediction of treatment response. 2. Suggestion about the optimal time to start treatment. 3. The data obtained will help to deepen our knowledge of the correlation among Lyso-Gb3, genotype and phenotype. 4. Better understanding of the pathophysiology of FD. To sum up, the results of the study will make a significant contribution to scientific knowledge providing new evidence with an immediate clinical application in FD patients. As well as, the project will serve as the basis for a large-scale project implementation to validate the results obtained

NCT ID: NCT04847622 Recruiting - Covid19 Clinical Trials

Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.

909REM
Start date: February 1, 2021
Phase:
Study type: Observational

This is a multi-centre, multi-country retrospective cohort study. At least 450COVID-19 cases from up to 20 participating study sites who meet all eligibility criteria will be included in the analysis. Deidentified data will be extracted from electronic medical record (EMR) databases, clinical registries, case series or additional sources from participating sites and countries, and then entered into a structured e-CRF system. addition, each site/country will be surveyed to determine the local standard of care therapy for COVID-19 infection and to determine if standard protocols were/are in place for the use of Remdesivir and if/how the protocols changed over time.

NCT ID: NCT04847284 Recruiting - Brain Metastases Clinical Trials

Intraoperative Radiotherapy in Patients With Brain Metastases

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

Intraoperative radiotherapy (IORT) is a new alternative for local radiotherapy with the advantages of dose escalation, reduced overall treatment time, and enhanced patient convenience, however the degree of efficacy is unknown, as well as and which is the most efficient dose. The objective of this study is to evaluate the efficacy and safety of IORT in patients with surgical excision of brain metastases at a dose of 20 Gy is at least as effective and safe as other forms of radiation therapy in patients with resection of brain metastases.